Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Annette Hayden is active.

Publication


Featured researches published by Annette Hayden.


Bioorganic & Medicinal Chemistry | 2011

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors

Hanae Benelkebir; Christopher Hodgkinson; Patrick J. Duriez; Annette Hayden; Rosemary A. Bulleid; Simon J. Crabb; Graham Packham; A. Ganesan

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.


The Journal of Pathology | 2015

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma

Timothy J. Underwood; Annette Hayden; Mathieu Derouet; Edwin Garcia; Fergus Noble; Michael J White; Steve Thirdborough; Abbie Mead; Nicholas J. Clemons; Massimiliano Mellone; Chudy Uzoho; John Primrose; Jeremy P. Blaydes; Gareth J. Thomas

Interactions between cancer cells and cancer‐associated fibroblasts (CAFs) play an important role in tumour development and progression. In this study we investigated the functional role of CAFs in oesophageal adenocarcinoma (EAC). We used immunochemistry to analyse a cohort of 183 EAC patients for CAF markers related to disease mortality. We characterized CAFs and normal oesophageal fibroblasts (NOFs) using western blotting, immunofluorescence and gel contraction. Transwell assays, 3D organotypic culture and xenograft models were used to examine the effects on EAC cell function and to dissect molecular mechanisms regulating invasion. Most EACs (93%) contained CAFs with a myofibroblastic (α‐SMA‐positive) phenotype, which correlated significantly with poor survival [p = 0.016; HR 7. 1 (1.7–29.4)]. Primary CAFs isolated from EACs have a contractile, myofibroblastic phenotype and promote EAC cell invasion in vitro (Transwell assays, p ≤ 0.05; organotypic culture, p < 0.001) and in vivo (p ≤ 0.05). In vitro, this pro‐invasive effect is modulated through the matricellular protein periostin. Periostin is secreted by CAFs and acts as a ligand for EAC cell integrins αvβ3 and αvβ5, promoting activation of the PI3kinase–Akt pathway. In patient samples, periostin expression at the tumour cell–stromal interface correlates with poor overall and disease‐free survival. Our study highlights the importance of the tumour stroma in EAC progression. Paracrine interaction between CAF‐secreted periostin and EAC‐expressed integrins results in PI3 kinase–Akt activation and increased tumour cell invasion. Most EACs contain a myofibroblastic CAF‐rich stroma; this may explain the aggressive, highly infiltrative nature of the disease, and suggests that stromal targeting may produce therapeutic benefit in EAC patients.


Bioorganic & Medicinal Chemistry | 2011

Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability

Hanae Benelkebir; Sabrina Marie; Annette Hayden; Jason Lyle; Paul M. Loadman; Simon J. Crabb; Graham Packham; A. Ganesan

The total synthesis of largazole and four analogues is reported. All analogues were nanomolar HDAC inhibitors. The antiproliferative activity is driven by lipophilicity and cell permeability. In murine liver homogenates, largazole is rapidly metabolized (half-life ≤5 min) to the thiol which has a half-life of 51 min.


Oncotarget | 2016

A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers

Christopher J. Hanley; Fergus Noble; Matthew Ward; Marc D. Bullock; Cole R. Drifka; Massimiliano Mellone; Antigoni Manousopoulou; Harvey E. Johnston; Annette Hayden; Stephen M. Thirdborough; Yuming Liu; David M. Smith; Toby Mellows; W. John Kao; Spiros D. Garbis; Alex H. Mirnezami; Timothy J. Underwood; Kevin W. Eliceiri; Gareth J. Thomas

Collagen structure has been shown to influence tumor cell invasion, metastasis and clinical outcome in breast cancer. However, it remains unclear how it affects other solid cancers. Here we utilized multi-photon laser scanning microscopy and Second Harmonic Generation to identify alterations to collagen fiber structure within the tumor stroma of head & neck, esophageal and colorectal cancers. Image segmentation algorithms were then applied to quantitatively characterize these morphological changes, showing that elongated collagen fibers significantly correlated with poor clinical outcome (Log Rank p < 0.05). We used TGF-β treatment to model fibroblast conversion to smooth muscle actin SMA-positive cancer associated fibroblasts (CAFs) and found that these cells induce the formation of elongated collagen fibers in vivo. However, proteomic/transcriptomic analysis of SMA-positive CAFs cultured ex-vivo showed significant heterogeneity in the expression of genes with collagen fibril organizing gene ontology. Notably, stratifying patients according to stromal SMA-positivity and collagen fiber elongation was found to provide a highly significant correlation with poor survival in all 3 cancer types (Log Rank p ≤ 0.003). In summary, we show that increased collagen fiber length correlates with poor patient survival in multiple tumor types and that only a sub-set of SMA-positive CAFs can mediate the formation of this collagen structure.


Urologic Oncology-seminars and Original Investigations | 2014

The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer

Annette Hayden; James Douglas; Matthew Sommerlad; Lawrence Andrews; Katherine Gould; Syed A. Hussain; Gareth J. Thomas; Graham Packham; Simon J. Crabb

OBJECTIVES Cisplatin is the key systemic chemotherapeutic agent used for bladder cancer, but chemoresistance is a major clinical problem. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) regulates various critical cellular processes, including cellular antioxidant response, cellular detoxification, and drug uptake/efflux. These processes, and the expression of multiple Nrf2 target genes, have been found to be associated with bladder cancer prognosis and chemotherapy resistance. We, therefore, investigated whether Nrf2 might regulate cisplatin resistance in bladder cancer. MATERIALS AND METHODS We first used bladder cancer cell lines, including a cisplatin-resistant RT112 subline (RT112-CP), to investigate Nrf2 expression and activation and its association with cisplatin response. We then undertook immunohistochemical analysis of a tissue microarray of archival bladder cancer radical cystectomy specimens to test the relevance of clinical Nrf2 expression to outcomes following either neoadjuvant chemotherapy and cystectomy or cystectomy alone. RESULTS Bladder cancer cell lines showed variable Nrf2 expression. Nrf2 expression was greater in RT112-CP cisplatin-resistant cells compared with that in parental RT112 cells. Nrf2 overexpression was functional in this model as it was associated with increased antioxidant response element reporter construct activity, Nrf2 target gene expression (metallothionein and glutathione reductase), and basal glutathione levels. Cisplatin resistance was associated with Nrf2 expression, and in RT112-CP cells, its depletion partially restored cisplatin sensitivity. We demonstrated increased cytoplasmic or nuclear Nrf2 expression or both in 32% of clinical bladder cancer samples compared with that in normal tissue samples. Expression of Nrf2 in bladder cancer following radical cystectomy was associated with unfavorable overall (median = 0.65 vs. 2.11 y, P = 0.045), bladder cancer-specific, and recurrence-free survival in those patients who also received neoadjuvant cisplatin-based chemotherapy but not in those treated with cystectomy alone. CONCLUSIONS Nrf2 overexpression in bladder cancer is associated with clinically relevant cisplatin resistance that is reversible in experimental models and should now be tested in prospective studies.


Scientific Reports | 2016

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

Edwin Garcia; Annette Hayden; Charles N. Birts; Edward Britton; Andrew Cowie; Karen Pickard; Massimiliano Mellone; Clarisa Choh; Mathieu F. Derouet; Patrick J. Duriez; Fergus Noble; Michael J White; John Primrose; Jonathan C. Strefford; Matthew J. Rose-Zerilli; Gareth J. Thomas; Yeng Ang; Andrew D. Sharrocks; Rebecca C. Fitzgerald; Timothy J. Underwood

New biological tools are required to understand the functional significance of genetic events revealed by whole genome sequencing (WGS) studies in oesophageal adenocarcinoma (OAC). The MFD-1 cell line was isolated from a 55-year-old male with OAC without recombinant-DNA transformation. Somatic genetic variations from MFD-1, tumour, normal oesophagus, and leucocytes were analysed with SNP6. WGS was performed in tumour and leucocytes. RNAseq was performed in MFD-1, and two classic OAC cell lines FLO1 and OE33. Transposase-accessible chromatin sequencing (ATAC-seq) was performed in MFD-1, OE33, and non-neoplastic HET1A cells. Functional studies were performed. MFD-1 had a high SNP genotype concordance with matched germline/tumour. Parental tumour and MFD-1 carried four somatically acquired mutations in three recurrent mutated genes in OAC: TP53, ABCB1 and SEMA5A, not present in FLO-1 or OE33. MFD-1 displayed high expression of epithelial and glandular markers and a unique fingerprint of open chromatin. MFD-1 was tumorigenic in SCID mouse and proliferative and invasive in 3D cultures. The clinical utility of whole genome sequencing projects will be delivered using accurate model systems to develop molecular-phenotype therapeutics. We have described the first such system to arise from the oesophageal International Cancer Genome Consortium project.


Urology | 2017

Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer

Regina Mora Vidal; Sergio Regufe da Mota; Annette Hayden; Hannah Markham; James Douglas; Graham Packham; Simon J. Crabb

OBJECTIVE To investigate perturbations in downstream signaling pathway activation and potential resistance mechanisms to epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) inhibition in cell line models of bladder cancer. METHODS We undertook a structured screening approach by phosphokinase array, followed by validation steps, to detect activated downstream signaling pathway nodes after therapeutic inhibition of EGFR or HER2 in bladder cancer cell lines. RESULTS Erlotinib treatment of RT112 cells induced phosphorylation of 9 activated phosphoprotein targets (p38 mitogen-activated protein kinase [MAPK] [Thr180/Tyr182], GSK-3α/β [Ser21/9], MEK1/2 [Ser218/222, Ser222/226], Akt (protein kinase B) [Ser473], TOR [target of rapamycin] [Ser2448], Src [Tyr419], p27 [Thr198], p27 [Thr157], and PLCγ-1 [Tyr783]), whereas STAT4 (signal transducer and activator of transcription 4) (Tyr693) phosphorylation was reduced. Of these, p38 MAPK phosphorylation was confirmed to occur in response to inhibition of either EGFR or HER2 signaling through multiple validation steps, including differing bladder cancer cell lines (RT112, UM-UC-3, and T24) and methods of receptor pathway inhibition (erlotinib, lapatinib, and siRNA depletion of EGFR or HER2). Chemical inhibition of p38 MAPK with SB203580 led to inhibition of proliferation in RT112, UM-UC-3, and T24 cell lines (IC50 20.85, 76.78, and 79.12 µM, respectively). Fractional effect analyses indicated a synergistic interaction for inhibition of cell proliferation when combining SB203580 with lapatinib. CONCLUSION p38 MAPK is a potential therapeutic target in bladder cancer and this strategy warrants further development in this disease. It may also allow combination therapy strategies to be developed in conjunction with EGFR or HER2 inhibition.


Gut | 2012

OC-121 Fibroblast activation in the tumour microenvironment promotes tumour cell invasion and resistance to chemotherapy in oesophageal adenocarcinoma

Annette Hayden; M F Derouet; Fergus Noble; John Primrose; J P Blaydes; Gareth J. Thomas; Timothy J. Underwood

Introduction Stromal and other non-malignant cells have the potential to undergo modifications that can synergistically create a supportive microenvironment for tumour growth, invasion and metastasis. Oesophageal adenocarcinoma (EAC) is characterised by early invasion, leading to metastatic disease and therefore only 20% of patients are suitable for treatment with curative intent. Cancer associated fibroblasts (CAFs) have an activated, myofibroblastic phenotype and have been recognised as mediators of tumour progression in a range of solid tumours. This study investigates the role of CAFs in EAC invasion and resistance to chemotherapy. Methods Functional biological analyses comparing primary fibroblasts from tumour stroma (CAF) and normal oesophagus (NOF) were carried out using organotypic culture, transwell invasion assays, collagen-1 gel contraction assays, siRNA gene silencing and colony forming assays. T-Tests (>95% CI) were carried out for all statistical analyses. Results Primary oesophageal CAFs displayed an activated phenotype as demonstrated by α-SMA expression and increased collagen-1 gel contraction in comparison to NOFs (p<0.01). CAF conditioned medium supported tumour colony formation in the presence of cisplatin and 5-Fluorouracil compared to NOF conditioned medium (p<0.05). Ex vivo analysis revealed a twofold (p<0.05) increase in EAC cell invasion in response to primary (CAF) conditioned medium in transwell invasion assays that was replicated in 3D organotypic models containing co-cultures of fibroblasts and EAC tumour cells. Down-regulation of the CAF secreted molecule Periostin (PN) resulted in a 70% reduction in tumour cell invasion in transwell assays (p<0.05), and a total loss of invasion in organotypic culture. Furthermore, collagen-1 gel contraction was abrogated by PN down-regulation. NOFs exposed to TGF-β from 72 h demonstrate features of myofibroblastic activation including, PN expression and the ability to support increased EAC tumour cell invasion (p<0.05). Conclusion This study has demonstrated that oesophageal derived primary CAF protect EAC cells from chemotherapy and promote tumour cell invasion. Increased α-SMA expression and collagen-1 gel contraction indicates CAF have a myofibroblast like phenotype. PN siRNA reduced gel contraction supports a hypothesis of autocrine regulation of the myofibroblast phenotype. Therefore targeting pathways that determine fibroblast activation may offer a novel therapy for preventing oesophageal cancer invasion and metastasis. Competing interests None declared.


Cancer Cell International | 2018

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models

Sergio Regufe da Mota; Sarah Bailey; Rosemary A. Strivens; Annette Hayden; Leon Douglas; Patrick J. Duriez; M. Teresa Borrello; Hanae Benelkebir; A. Ganesan; Graham Packham; Simon J. Crabb

BackgroundCastrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such as enzalutamide as a result. The lysine demethylase LSD1 is a co-activator of the wild type androgen receptor and a potential therapeutic target in hormone sensitive prostate cancer. We evaluated whether LSD1 could also be therapeutically targeted in CRPC models driven by AR-V7.MethodsWe utilised cell line models of castrate resistant prostate cancer through over expression of AR-V7 to test the impact of chemical LSD1 inhibition on AR activation. We validated findings through depletion of LSD1 expression and in prostate cancer cell lines that express AR-V7.ResultsChemical inhibition of LSD1 resulted in reduced activation of the androgen receptor through both the wild type and its AR-V7 splice variant forms. This was confirmed and validated in luciferase reporter assays, in LNCaP and 22Rv1 prostate cancer cell lines and in LSD1 depletion experiments.ConclusionLSD1 contributes to activation of both the wild type and V7 splice variant forms of the androgen receptor and can be therapeutically targeted in models of CRPC. Further development of this approach is warranted.


Scientific Reports | 2017

Fibroblasts derived from oesophageal adenocarcinoma differ in DNA methylation profile from normal oesophageal fibroblasts

Eric Smith; Helen M. Palethorpe; Annette Hayden; Joanne Young; Timothy J. Underwood; Paul A. Drew

Oesophageal adenocarcinoma (OAC) is increasing in incidence and has a poor prognosis. Tumour derived fibroblasts (TDFs) differ functionally from normal fibroblasts (NDFs), and play a pivotal role in cancer. Many of the differences persist through subculture. We measured the DNA methylation profiles of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa using Infinium HumanMethylation450 Beadchips and found they differed in multidimensional scaling analysis. We identified 4,856 differentially methylated CpGs (DMCs, adjusted p < 0.01 and absolute difference in average β-value > 0.15), of which 3,243 (66.8%) were hypomethylated in TDFs compared to NDFs. Hypermethylated DMCs were enriched at transcription start sites (TSSs) and in CpG islands, and depleted in transcriptional enhancers. Gene ontology analysis of genes with DMCs at TSSs revealed an enrichment of genes involved in development, morphogenesis, migration, adhesion, regulation of processes and response to stimuli. Alpha-smooth muscle actin (α-SMA) is a marker of activated fibroblasts and a poor prognostic indicator in OAC. Hypomethylated DMCs were observed at the TSS of transcript variant 2 of α-SMA, which correlated with an increase in α-SMA protein expression. These data suggest that DNA methylation may contribute to the maintenance of the TDF phenotype.

Collaboration


Dive into the Annette Hayden's collaboration.

Top Co-Authors

Avatar

Graham Packham

University of Southampton

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Simon J. Crabb

University of Southampton

View shared research outputs
Top Co-Authors

Avatar

Fergus Noble

University of Southampton

View shared research outputs
Top Co-Authors

Avatar

John Primrose

University of Southampton

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Ganesan

University of East Anglia

View shared research outputs
Top Co-Authors

Avatar

Edwin Garcia

University of Southampton

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge